To compare the effectiveness of the topical use of cyclosporin A (CsA) 0.1%, diquafosol (DQS) tetrasodium 3% ophthalmic solution, and their combination in treating dry eye disease in a general health care setting.
Methods:
This prospective, nonrandomized, observational study analyzed 279 patients. Patients instilled topical CsA 0.1% (Ikervis®; Santen Pharmaceutical Co., Ltd., Japan) once daily and/or DQS tetrasodium 3% (Diquas-S®; Santen) six times a day for 12 weeks. Objective signs [tear break-up time (TBUT), National Eye Institute (NEI) corneal and conjunctival staining scores] and symptoms [Symptom Assessment in Dry Eye (SANDE) and Dry Eye-related Quality-of-Life Score (DEQS) questionnaires] were evaluated at baseline, week 4, and week 12.
Results:
Patients (n = 279) were mainly female (85.0%) with a mean (SD) age of 50.1 (14.8) years, and received CsA (n = 93), DQS (n = 99), or CsA/DQS (n = 87). Both monotherapies and CsA/DQS combination therapy significantly improved TBUT, NEI corneal and conjunctival staining scores, and SANDE and DEQS scores from baseline to week 12 (all P < 0.0001). The mean change in TBUT between baseline and week 12 was significantly higher in CsA/DQS combination therapy (2.13 ± 2.41 s) than in CsA monotherapy (1.07 ± 1.71 s; P = 0.0011).
Conclusions:
Monotherapy with CsA or DQS and CsA/DQS combination therapy all significantly improved the objective signs and symptoms of dry eyes during 12 weeks of treatment. CsA/DQS combination therapy provides an additional benefit in terms of TBUT compared with CsA alone; however, a randomized controlled trial still needs to be performed to confirm this result.
Get full access to this article
View all access options for this article.
References
1.
WillcoxMDP, ArgüesoP, GeorgievGA, et al.TFOS DEWS II tear film report. Ocul Surf, 2017; 15(3):366–403; doi: 10.1016/j.jtos.2017.03.006
2.
CraigJP, NicholsKK, AkpekEK, et al.TFOS DEWS II definition and classification report. Ocul Surf, 2017; 15(3):276–283; doi: 10.1016/j.jtos.2017.05.008
3.
HyonJY, KimHM, LeeD, et al.Korean guidelines for the diagnosis and management of dry eye: Development and validation of clinical efficacy. Korean J Ophthalmol, 2014; 28(3):197–206; doi: 10.3341/kjo.2014.28.3.197
4.
BronAJ, de PaivaCS, ChauhanSK, et al.TFOS DEWS II pathophysiology report. Ocul Surf, 2017; 15(3):438–510; doi: 10.1016/j.jtos.2017.05.011
5.
UchinoM, SchaumbergDA. Dry eye disease: Impact on quality of life and vision. Curr Ophthalmol Rep, 2013; 1(2):51–57; doi: 10.1007/s40135-013-0009-1
6.
McDonaldM, PatelDA, KeithMS, et al.Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: A systematic literature review. Ocul Surf, 2016; 14(2):144–167; doi: 10.1016/j.jtos.2015.11.002
7.
JonesL, DownieLE, KorbD, et al.TFOS DEWS II management and therapy report. Ocul Surf, 2017; 15(3):575–628; doi: 10.1016/j.jtos.2017.05.006
8.
KimM, LeeY, MehraD, et al.Dry eye: Why artificial tears are not always the answer. BMJ Open Ophthalmol, 2021; 6(1):e000697; doi: 10.1136/bmjophth-2020-000697
9.
CutoloCA, BarabinoS, BonzanoC, et al.The use of topical corticosteroids for treatment of dry eye syndrome. Ocul Immunol Inflamm, 2019; 27(2):266–275; doi: 10.1080/09273948.2017.1341988
10.
TuanHI, ChiSC, KangYN. An updated systematic review with meta-analysis of randomized trials on topical cyclosporin a for dry-eye disease. Drug Des Devel Ther, 2020; 14:265–274; doi: 10.2147/dddt.S207743
11.
LeonardiA, Van SettenG, AmraneM, et al.Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: A multicenter randomized trial. Eur J Ophthalmol, 2016; 26(4):287–296; doi: 10.5301/ejo.5000779
12.
BaudouinC, de la MazaMS, AmraneM, et al.One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol, 2017; 27(6):678–685; doi: 10.5301/ejo.5001002
13.
HindJ, MacdonaldE, LockingtonD. Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease. Eye (Lond), 2019; 33(4):685–686; doi: 10.1038/s41433-018-0289-7
14.
KeatingGM.Diquafosol ophthalmic solution 3%: A review of its use in dry eye. Drugs, 2015; 75(8):911–922; doi: 10.1007/s40265-015-0409-7
MatsumotoY, OhashiY, WatanabeH, et al.Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: A Japanese phase 2 clinical trial. Ophthalmology, 2012; 119(10):1954–1960; doi: 10.1016/j.ophtha.2012.04.010
17.
KamiyaK, NakanishiM, IshiiR, et al.Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: A prospective, randomized, multicenter study. Eye (Lond), 2012; 26(10):1363–1368; doi: 10.1038/eye.2012.166
18.
TakamuraE, TsubotaK, WatanabeH, et al.A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol, 2012; 96(10):1310–1315; doi: 10.1136/bjophthalmol-2011-301448
19.
GongL, SunX, MaZ, et al.A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol, 2015; 99(7):903–908; doi: 10.1136/bjophthalmol-2014-306084
20.
ParkDH, ChungJK, SeoDR, et al.Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: A randomized controlled trial. Am J Ophthalmol, 2016; 163:122–131.e2; doi: 10.1016/j.ajo.2015.12.002
21.
KimS, ShinJ, LeeJE. A randomised, prospective study of the effects of 3% diquafosol on ocular surface following cataract surgery. Sci Rep, 2021; 11(1):9124; doi: 10.1038/s41598-021-88589-7
22.
KohS, MaedaN, IkedaC, et al.Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol, 2014; 92(8):e671–e675; doi: 10.1111/aos.12443
23.
MunY, KwonJW, OhJY. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease. BMC Ophthalmol, 2018; 18(1):237; doi: 10.1186/s12886-018-0910-3
24.
EomY, KimHM. Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: A multicenter prospective observational study. Int J Ophthalmol, 2021; 14(10):1518–1526; doi: 10.18240/ijo.2021.10.07
25.
FedericiTJ.The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease. Pharmacol Res, 2011; 64(6):614–623; doi: 10.1016/j.phrs.2011.06.013
26.
YangWJ, YangYN, CaoJ, et al.Risk factors for dry eye syndrome: A retrospective case-control study. Optom Vis Sci, 2015; 92(9):e199–e205; doi: 10.1097/opx.0000000000000541
27.
TanriverdiC, Nurozler TabakciB, DonmezS.Longitudinal assessment of meibomian glands and tear film layer in systemic isotretinoin treatment. Eur J Ophthalmol, 2021;11206721211018361; doi: 10.1177/11206721211018361
28.
EomY, HyonJY, LeeHK, et al.A multicenter cross-sectional survey of dry eye clinical characteristics and practice patterns in Korea: The DECS-K study. Jpn J Ophthalmol, 2021; 65(2):261–270; doi: 10.1007/s10384-020-00803-7
29.
MilnerMS, BeckmanKA, LuchsJI, et al.Dysfunctional tear syndrome: Dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment. Curr Opin Ophthalmol, 2017; 27 (Suppl 1):3–47; doi: 10.1097/01.icu.0000512373.81749.b7
30.
AlshammeriS, MaddenL, HaganS, et al.Strip meniscometry tube: A rapid method for assessing aqueous deficient dry eye. Clin Exp Optom, 2020; 103(4):469–473; doi: 10.1111/cxo.12941
31.
LempMA, CrewsLA, BronAJ, et al.Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea, 2012; 31(5):472–478; doi: 10.1097/ICO.0b013e318225415a
32.
BehrensA, DoyleJJ, SternL, et al.Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. Cornea, 2006; 25(8):900–907; doi: 10.1097/01.ico.0000214802.40313.fa
33.
TsubotaK.Short tear film breakup time-type dry eye. Invest Ophthalmol Vis Sci, 2018; 59(14):Des64–Des70; doi: 10.1167/iovs.17-23746
34.
GulatiA, SullivanR, BuringJE, et al.Validation and repeatability of a short questionnaire for dry eye syndrome. Am J Ophthalmol, 2006; 142(1):125–131; doi: 10.1016/j.ajo.2006.02.038
35.
SchaumbergDA, GulatiA, MathersWD, et al.Development and validation of a short global dry eye symptom index. Ocul Surf, 2007; 5(1):50–57; doi: 10.1016/s1542-0124(12)70053-8
36.
SakaneY, YamaguchiM, YokoiN, et al.Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol, 2013; 131(10):1331–1338; doi: 10.1001/jamaophthalmol.2013.4503
37.
EomY, NaKS, HwangHS, et al.Clinical efficacy of eyelid hygiene in blepharitis and meibomian gland dysfunction after cataract surgery: A randomized controlled pilot trial. Sci Rep, 2020; 10(1):11796; doi: 10.1038/s41598-020-67888-5
38.
LempMA.Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao j, 1995; 21(4):221–232.
39.
BronAJ, EvansVE, SmithJA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea, 2003; 22(7):640–650; doi: 10.1097/00003226-200310000-00008
40.
ParkCH, KimMK, KimEC, et al.Efficacy of topical cyclosporine nanoemulsion 0.05% compared with topical cyclosporine emulsion 0.05% and diquafosol 3% in dry eye. Korean J Ophthalmol, 2019; 33(4):343–352; doi: 10.3341/kjo.2018.0116
41.
PerryHD, SolomonR, DonnenfeldED, et al.Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol, 2008; 126(8):1046–1050; doi: 10.1001/archopht.126.8.1046
42.
FoulksGN, ForstotSL, DonshikPC, et al.Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf, 2015; 13(2):118–132; doi: 10.1016/j.jtos.2014.12.001
43.
PflugfelderSC, De PaivaCS, VillarrealAL, et al.Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea, 2008; 27(1):64–69; doi: 10.1097/ICO.0b013e318158f6dc
44.
RhimJW, EomY, YoonEG, et al.Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction. Jpn J Ophthalmol, 2022; 66(3):254–263; doi: 10.1007/s10384-022-00906-3
45.
KohS, IkedaC, TakaiY, et al.Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol, 2013; 57(5):440–446; doi: 10.1007/s10384-013-0251-y
46.
AritaR, SuehiroJ, HaraguchiT, et al.Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol, 2013; 97(6):725–729; doi: 10.1136/bjophthalmol-2012-302668
47.
JiYW, KimHM, RyuSY, et al.Changes in human tear proteome following topical treatment of dry eye disease: Cyclosporine A versus diquafosol tetrasodium. Invest Ophthalmol Vis Sci, 2019; 60(15):5035–5044; doi: 10.1167/iovs.19-27872
48.
YangJM, ChoiW, KimN, et al.Comparison of topical cyclosporine and diquafosol treatment in dry eye. Optom Vis Sci, 2015; 92(9):e296–e302; doi: 10.1097/opx.0000000000000657
49.
UtsunomiyaT, KawaharaA, HanadaK, et al.Effects of diquafosol ophthalmic solution on quality of life in dry eye assessed using the Dry Eye-Related Quality-of-Life Score questionnaire: Effectiveness in patients while reading and using visual display terminals. Cornea, 2017; 36(8):908–914; doi: 10.1097/ico.0000000000001241
50.
BaudouinC, FigueiredoFC, MessmerEM, et al.A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol, 2017; 27(5):520–530; doi: 10.5301/ejo.5000952
51.
IbrahimOM, DogruM, WardSK, et al.The efficacy, sensitivity, and specificity of strip meniscometry in conjunction with tear function tests in the assessment of tear meniscus. Invest Ophthalmol Vis Sci, 2011; 52(5):2194–2198; doi: 10.1167/iovs.10-5986
52.
DogruM, IshidaK, MatsumotoY, et al.Strip meniscometry: A new and simple method of tear meniscus evaluation. Invest Ophthalmol Vis Sci, 2006; 47(5):1895–1901; doi: 10.1167/iovs.05-0802
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
